Placebo is formulated as 100 mg placebo in a 20 mL vial. The matching placebo has the same formulation as the drug product except it contains no XTMAB-16.
Sponsors
Xentria Inc.
Conditions
Pulmonary sarcoidosis with or without extrapulmonary manifestations
Phase 1
A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations
WithdrawnCTIS2022-502877-41-00
Target: 47Updated: 2023-09-04
A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations
RecruitingCTIS2022-502877-41-01
Start: 2025-02-10Target: 24Updated: 2025-07-18